Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma? Consortium for Improving Survival of Lymphoma (CISL) study

Myeong Seok Koh, Won Seog Kim, Seok Jin Kim, Sung Yong Oh, Dok Hyun Yoon, Soon Il Lee, Junshik Hong, Moo Kon Song, Ho Jin Shin, Jung Hye Kwon, Hyo Jung Kim, Yong Rok Do, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96–100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7–168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8–197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9–121.9 months) and the OS was 137.3 months (95 % CI 127.9–146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy.

Original languageEnglish (US)
Pages (from-to)420-425
Number of pages6
JournalInternational Journal of Hematology
Volume102
Issue number4
DOIs
StatePublished - Oct 1 2015

Bibliographical note

Funding Information:
This paper was supported by the JW Pharmacy Research Fund.

Publisher Copyright:
© 2015, The Japanese Society of Hematology.

Keywords

  • B cell lymphoma
  • Chemotherapy
  • Local stage
  • Marginal zone

Fingerprint

Dive into the research topics of 'Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma? Consortium for Improving Survival of Lymphoma (CISL) study'. Together they form a unique fingerprint.

Cite this